Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (1,248) Arrow Down
Filter Results: (1,248) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,248)
    • People  (5)
    • News  (172)
    • Research  (929)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (759)

Show Results For

  • All HBS Web  (1,248)
    • People  (5)
    • News  (172)
    • Research  (929)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (759)
← Page 28 of 1,248 Results →
  • February 2010 (Revised September 2011)
  • Case

Roche's Acquisition of Genentech

By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Citation
Educators
Purchase
Related
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
  • February 2024
  • Case

Compass Pathways: Pioneering Psychedelic Treatment

By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
Citation
Educators
Purchase
Related
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
  • Web

Strategy for Health Care Delivery - Institute For Strategy And Competitiveness

Clinic) as part of their business model Senior executives from nonprofit organizations that deliver health care services Executives from health care insurance companies, government entities that pay for health care, or other payor organizations Leaders from View Details
  • June 2004 (Revised June 2006)
  • Supplement

Vertex Pharmaceuticals: R&D Portfolio Management (A)

By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details
Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry
Citation
Purchase
Related
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
  • Web

Value Measurement for Health Care - Institute For Strategy And Competitiveness

part of their business model Executives from health care insurance companies, government entities that pay for health care, or other payor organizations Leaders from pharmaceutical companies, medical device companies, or other health care... View Details
  • September 1990 (Revised November 1991)
  • Case

Merck & Co., Inc. (B)

In late 1986, Merck revised its performance review and pay practices. The most important change was a shift from an absolute rating system to a forced-distribution system in which managers are forced to adhere to a given distribution of performance ratings. Other major... View Details
Keywords: Performance Evaluation; Compensation and Benefits; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Murphy, Kevin J. "Merck & Co., Inc. (B)." Harvard Business School Case 491-006, September 1990. (Revised November 1991.)
  • 01 Jun 2023
  • News

From Big Pharma to Startup

pharmaceutical giant one day—not creating a company from scratch. But Goble was determined to explore the wide variety of opportunities available to him in his time at HBS, so when he read about a nonprofit life sciences entrepreneurship... View Details
Keywords: April White

    Stephen P. Bradley

    Professor Bradley is the William Ziegler Professor of Business Administration Emeritus at the Harvard Business School. In addition to teaching Management and Strategy in the Owner President Management Program and leading an... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
    • 01 Sep 2007
    • News

    Alfred D. Chandler Jr. Remembered

    Matsushita. That volume was followed in 2005 by Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. “Such science-based industries have had as much impact on this... View Details
    • 31 May 2023
    • News

    Alumni Achievement Awards 2023

    A. Schwarzman (MBA 1972) Reshma Kewalramani MD, FASN (GMP 18, 2015) CEO and President, Vertex Pharmaceuticals Big move: “I was almost 12 when we flew from Bombay to the United States. My impressions of the West came from the movie Grease... View Details
    Keywords: leadership; management; work-life balance
    • November 2016
    • Case

    Transformation at Eli Lilly & Co. (A)

    By: William R. Kerr and Alexis Brownell
    Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly sets out on a dramatic transformation process in 2009. The case considers how Lilly restructured the organization into business areas to aid better decision-making,... View Details
    Keywords: Eli Lilly; Restructuring; R&D; Transformation; Organizational Change and Adaptation; Organizational Structure; Pharmaceutical Industry; Indianapolis
    Citation
    Educators
    Purchase
    Related
    Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (A)." Harvard Business School Case 817-070, November 2016.
    • October 2000 (Revised March 2003)
    • Case

    Merck & Company: Evaluating a Drug Licensing Opportunity

    By: Richard S. Ruback and David B Krieger
    This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
    Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
    • January 1998 (Revised February 2006)
    • Background Note

    Creating Competitive Advantage

    By: Pankaj Ghemawat and Jan W. Rivkin
    A firm such as Schering-Plough that earns superior, long-run financial returns within its industry is said to enjoy a competitive advantage over its rivals. This note examines the logic of how firms create competitive advantage. It emphasizes two themes: First, to... View Details
    Keywords: Competitive Advantage; Competitive Strategy; Management; Business Strategy; Growth and Development Strategy; Innovation Strategy; Management Practices and Processes; Value Creation; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Ghemawat, Pankaj, and Jan W. Rivkin. "Creating Competitive Advantage." Harvard Business School Background Note 798-062, January 1998. (Revised February 2006.)
    • Web

    Research - Health Care

    UAE for fibroids or adenomyosis were captured from electronic health record timestamps and... May 2024 Article Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms By: Caroline Marra... View Details
    • April 2011 (Revised April 2015)
    • Case

    Cipla 2011

    By: Rohit Deshpande, Sandra J. Sucher and Laura Winig
    Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape. View Details
    Keywords: Leadership; Leading Change; Leadership Style; Management Teams; Governance Compliance; Corporate Strategy; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Deshpande, Rohit, Sandra J. Sucher, and Laura Winig. "Cipla 2011." Harvard Business School Case 511-050, April 2011. (Revised April 2015.)

      William E. Fruhan

      Professor WILLIAM E. FRUHAN, JR. is George E. Bates Professor, Emeritus at the Harvard Business School. He received his BS degree from Yale University, and his MBA and DBA degrees from Harvard University.  He has served as Senior Associate Dean and Director of... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • 01 Oct 2021
      • News

      From Scholarship to Life-Saving Impact

      ending up with huge medical bills we couldn’t pay.” Inspired by this personal experience, Rabah chose to build a career in health care. She studied biology as an undergraduate at Cornell, where she developed a strong interest in drug pricing and View Details
      • Web

      Request more information | HBS Courses | HBS Online

      Aerospace/Defense Agriculture Auto Communications E-Commerce E-Education Energy Entertainment Financial Services Food/Beverage Health/Medical Hospitality Insurance Manufacturing Non-Profit Pharmaceuticals Professional Services Retail... View Details
      • Web

      Strategy Awards & Honors - Faculty & Research

      her paper with Ian Cockburn, "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research" ( Strategic Management Journal , 1994). The award is for a paper published five or more years prior so that the paper's impact on... View Details
      • 22 Nov 2004
      • Research & Ideas

      Side Effects: The Case of Propecia

      You are the marketing director of Propecia, a new drug for hair restoration that's about to hit the market. But the drug can only be purchased via a physician's prescription. So do you advertise directly to balding men? Do you concentrate on targeting physicians? How... View Details
      Keywords: by Sean Silverthorne; Pharmaceutical; Pharmaceutical
      • ←
      • 28
      • 29
      • …
      • 62
      • 63
      • →
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College.